FDA Approves First All-Oral AML Therapy, Shifting Treatment from Clinic to Home

PRINCETON, NJ – May 14, 2026 – The U.S. Food and Drug Administration (FDA) has approved a landmark all-oral treatment for a vulnerable group of cancer patients, signaling a significant shift in how acute myeloid leukemia (AML) can be managed. The new approval is for INQOVI (decitabine and cedazuridine) in combination with venetoclax for adults with newly diagnosed AML who are 75 years or older, or who have comorbidities that prevent them from undergoing intensive chemotherapy.

Developed by Taiho Oncology, Inc. and its parent company Taiho Pharmaceutical Co., Ltd., this regimen is the first and only entirely oral combination therapy approved for this specific patient population. The approval offers a long-awaited alternative to treatments that require frequent and burdensome visits to hospitals or infusion centers, potentially transforming the standard of care and improving the quality of life for thousands of patients annually.

“This FDA approval represents a significant milestone for patients with newly diagnosed acute myeloid leukemia who are not candidates for intensive induction chemotherapy,” said Peter Melnyk, President and Chief Executive Officer of Taiho Oncology, in a statement. “With the approval of an all-oral regimen, INQOVI in combination with venetoclax brings a new treatment option to this patient population.”

A New Era of Convenience for Vulnerable Patients

Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow that primarily affects older adults. While intensive induction chemotherapy can be curative for younger, healthier patients, it is often too toxic for those who are elderly or frail. For this group, who make up more than half of the estimated 22,720 new AML cases in the U.S. each year, treatment options have been limited and often involved significant logistical challenges.

The previous standard of care for these patients often involved a combination of the oral drug venetoclax with a hypomethylating agent (HMA) like azacitidine, which must be administered via injection or infusion over several consecutive days each month. This regimen tethers patients to a clinical setting, demanding frequent travel and time away from home, a considerable burden for those already battling a serious illness.

The new all-oral combination of INQOVI and venetoclax allows patients to take their treatment entirely at home. This shift from clinic-based to home-based care is seen by many oncologists as a revolutionary step. For patients, it means fewer logistical hurdles, reduced travel costs, less time spent in waiting rooms, and a lower risk of exposure to infections in a hospital environment.

“The ability to treat these patients with an entirely oral regimen is the most attractive thing about this combination,” noted one hematologist-oncologist familiar with the data. The convenience factor, they added, could make this a “potential new standard of care” for this specific AML population, fundamentally changing the conversation around treatment from one of endurance to one of manageability and independence.

A Synergistic Attack on Leukemia Cells

The effectiveness of the new therapy lies in the powerful synergy between its two components, which attack the cancer through distinct but complementary mechanisms.

INQOVI itself is a clever combination of two molecules. It contains decitabine, a well-established HMA that works by reactivating tumor-suppressor genes that cancer cells have silenced. However, decitabine is normally broken down in the gut and liver, requiring it to be given intravenously. INQOVI solves this problem by pairing it with cedazuridine, an inhibitor that protects decitabine from degradation, allowing it to be absorbed effectively when taken as a pill.

The second drug, venetoclax, is a targeted therapy known as a BCL-2 inhibitor. Many cancer cells, including AML cells, rely on the BCL-2 protein to evade apoptosis, the body’s natural process of programmed cell death. Venetoclax blocks this protein, essentially telling the cancer cells to die. Research has shown that HMAs like decitabine can make leukemia cells even more dependent on BCL-2 for survival, thus sensitizing them to the effects of venetoclax. This creates a potent one-two punch where decitabine sets the cancer cells up, and venetoclax delivers the knockout blow.

The Data Behind the Decision

The FDA’s approval was based on compelling results from the Phase 2 ASCERTAIN-V study, which evaluated the all-oral combination in 101 patients with newly diagnosed AML who were ineligible for intensive chemotherapy.

The study demonstrated significant efficacy. A total of 41.6% of patients achieved a complete remission (CR), meaning no evidence of leukemia. When including patients who achieved complete remission with incomplete blood count recovery (CRi), the overall response rate climbed to 63.4%. The responses were also rapid and durable; the median time to achieve a complete remission was just two months, and at the time of analysis, the median duration of that remission had not yet been reached, suggesting long-lasting benefits for many responders.

While effective, the treatment comes with significant risks that require careful management. The combination can cause severe myelosuppression, a decrease in the production of red blood cells, white blood cells, and platelets. In the study, the most common serious adverse reactions included febrile neutropenia (fever with low white blood cell count), sepsis, and pneumonia. The prescribing information includes a warning for these risks, and patients undergoing treatment will require close monitoring of their blood counts. Despite these risks, the safety profile was considered manageable and consistent with the known effects of the individual drugs, with no unexpected safety concerns arising from the combination.

Reshaping the Market and Future of Cancer Care

The approval of INQOVI plus venetoclax solidifies Taiho Oncology’s position as a leader in the development of oral anti-cancer therapies and directly addresses a major unmet need in hematology. By offering a less burdensome, equally effective alternative to the current standard of care, the company is poised to capture a significant portion of the market for treating elderly and frail AML patients.

This development is also part of a broader, transformative trend in oncology toward oral medications and the decentralization of care. As more therapies move from intravenous infusions to pills, the paradigm of cancer treatment is shifting away from the hospital and toward the patient's home. This not only improves convenience but also empowers patients to take a more active role in their own care.

“This approval marks an important step forward in expanding how treatment can be delivered for this patient population, offering an all-oral option that can potentially reduce the overall treatment burden associated with receiving treatment in hospitals or infusion centers,” stated Harold Keer, MD, PhD, Chief Medical Officer of Taiho Oncology. “We believe this approach has the potential to make a meaningful impact for patients and caregivers.”